膀胱灌注免疫毒素与丝裂霉素C对膀胱癌复发的预防作用

Intravesical administration of immunotoxin vs mitomycin-c as adjuvant therapy to the recurrence of bladder transitional cell carcinoma

目的探讨膀胱灌注免疫毒素对膀胱癌复发的预防作用。方法用抗人膀胱癌单克隆抗体BDI-1与蓖麻毒素（RT）通过化学交联制备的抗人膀胱癌免疫毒素BDI-1．RT。将106例膀胱癌患者分两组，其中52例膀胱癌患者进行膀胱灌注免疫毒素的导向治疗，另54例患者进行丝裂霉素C灌注治疗。随访3—24个月，平均19．2个月。结果免疫毒素用药组1例复发（1．9％）；丝裂霉素C用药组7例复发（13．O％）；两组复发率差异有统计学意义（P〈0．05）。结论免疫毒素BDI-1-RT可能是更好地预防膀胱肿瘤复发的药物。

Objective To evaluate the effect of conjugate imunotoixn BDI-1-RT given intravesically to prevent bladder cancer from recurrence in postoperative patients. Methods An anti-human immunotoxin against bladder carcinoma, BDI-1 -RT, was prepared and its in vitro targeting cytotoxicity estimated. After safety test, intravesical administration of immunotoxin BDI-1-RT was performed in 52 patients, and mitomycin C （MMC） was used in 54 patients serving as a control group. All patients were followed up for 3-24 months （ mean 19.2 months）. Results There was significant difference between the BDI-1-RT group （ 1.9% ） and MMC group （ 13.0% ） in recurrence rate （P 〈 0.05 ）. Conclusion BDI-1-RT may be used as a potent cytotoxic agent in the recurrence of bladder transition cell carcinoma.